Traws Pharma, Inc. Restructuring and Related Cost, Number of Positions Eliminated
Traws Pharma, Inc. (TRAW) had Restructuring and Related Cost, Number of Positions Eliminated of 11 item as of 2024-04-08, per its 10-Q filed 2024-11-14.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated · last filed 2025-03-31
- Traws Pharma, Inc. restructuring and related cost, number of positions eliminated for the quarter ending 2019-03-31 was 6.00 employee.
employee
| Period end | Restructuring and Related Cost, Number of Positions Eliminated 1 month | Restructuring and Related Cost, Number of Positions Eliminated 2 month | Restructuring and Related Cost, Number of Positions Eliminated 3 month | Restructuring and Related Cost, Number of Positions Eliminated 4 month |
|---|---|---|---|---|
| 2020-12-31 | 10.00 employee 10-K · filed 2022-03-21 | |||
| 2019-03-31 | 6.00 employee 10-Q · filed 2019-08-14 | 6.00 employee 10-Q · filed 2019-11-12 | 6.00 employee 10-K · filed 2021-03-18 | |
| 2019-02-28 | 6.00 employee 10-Q · filed 2019-08-14 |
pure
| Period end | Restructuring and Related Cost, Number of Positions Eliminated 3 month | Restructuring and Related Cost, Number of Positions Eliminated 9 month |
|---|---|---|
| 2020-09-30 | 600.00% 10-Q · filed 2020-11-16 | |
| 2019-03-31 | 600.00% 10-Q · filed 2020-08-12 |
item
| Period end | Restructuring and Related Cost, Number of Positions Eliminated |
|---|---|
| 2024-04-08 | 11.00 item 10-Q · filed 2024-11-14 |
USD
| Period end | Restructuring and Related Cost, Number of Positions Eliminated |
|---|---|
| 2024-04-08 | $11.00 10-K · filed 2025-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |